[SOPHE Leadership] CDC RFP (fwd)

[Keven Mosley-Koehler]

Hi Cezanne - do you happen to have a sophe logo we can use for the Save the 
Date postcard?  also, what do you and Laura think of the attached postcard?  
I would like to get it sent out next weekend...thank you...one side is 
front, other is back.


>From: Cezanne Garcia <ccgarcia at u.washington.edu>
>Reply-To: pnwhealth at u.washington.edu
>To: "Pacific Northwest Health Educators" <pnwhealth at u.washington.edu>
>Subject: [SOPHE Leadership] CDC RFP (fwd)
>Date: Thu, 6 Jun 2002 17:57:01 -0700 (Pacific Daylight Time)
>
>
> > Reducing Sexual Risk for HIV Transmission in Substance-Using Men Who 
>Have
> > Sex With Men
> > Primary Sponsor: Centers for Disease Control
> > Deadline: 7/31/2002
> >
> >
> > [Program Announcement 02136]
>Contact information at bottom of email.
>
> > A. Purpose
> >
> > The Centers for Disease Control and Prevention (CDC) announces the
> > availability of fiscal year (FY) 2002 funds for a cooperative agreement
> > program to support research on interventions to reduce sexual risk for 
>HIV
> > transmission in substance-using men who have sex with men (MSM). This
> > program addresses the ``Healthy People 2010'' focus HIV.
> >
> > The purpose of the research is to develop and test behavioral
> > interventions that focus on reducing risk for HIV transmission by 
>altering
> > the sexual risk behavior of substance using and abusing MSM. Under this
> > program, the primary outcome of the project will be the development of
> > effective interventions for substance-using MSM which may then be 
>adapted
> > and replicated by community-based HIV prevention and substance abuse
> > agencies among sub-populations of substance-using MSM throughout the 
>U.S.
> > This announcement addresses goals of CDC's HIV Prevention Strategic 
>Plan.
> >
> > Measurable outcomes of the program will be in alignment with one or more
> > of the following performance goals for the National Center for HIV, STD 
>&
> > TB Prevention. Through the implementation of HIV prevention programs,
> > reduce the number of cases of HIV infection and AIDS: 1. acquired
> > heterosexually, 2. related to injecting drug use, 3. associated with
> > male-to-male homosexual contact, and 4. acquired perinatally.
> >
> > B. Eligible Applicants
> >
> > Applications may be submitted by public and private nonprofit
> > organizations and by governments and their agencies; that is,
> > universities, colleges, research institutions, hospitals, other public 
>and
> > private nonprofit organizations, faith-based organizations, State and
> > local governments or their bona fide agents, including the District of
> > Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the
> > Commonwealth of Samoa, Guam, the Federated States of Micronesia, the
> > Republic of the Marshall Islands, and the Republic of Palau, and 
>federally
> > recognized Indian tribal governments, Indian tribes, or Indian tribal
> > organizations.
> >
> > Note:
> >
> > Title 2 of United States Code Section 1611 states that an organization
> > described in section 501(c)(4) of the Internal Revenue Code of 1986 that
> > engages in lobbying activities is not eligible to receive Federal funds
> > constituting an award, grant or loan.
> >
> > C. Availability of Funds
> >
> > Approximately $1,200,000 is expected to be available in FY 2002 to fund 
>up
> > to four awards for the first year of project activities. It is expected
> > that the average award will be approximately $300,000 in the first year 
>to
> > support development of an intervention in additional years and will 
>begin
> > on or before September 30, 2002. The award will be made for a 12-month
> > budget period, within a project period of up to five years. Funding
> > estimates are expected to increase once recruitment and intervention
> > activities begin. Continuation awards within an approved project period
> > will be made on the basis of satisfactory progress as evidenced by
> > required reports, satisfactory participant accrual, and the availability
> > of funds. The Catalog of Federal Domestic Assistance number is 93.943.
> >
> > Funding Preference
> >
> > Funding decisions will attempt to achieve regional diversity of the four
> > sites (e.g., Northeast, South, Central, West). Funding decisions will 
>also
> > take into consideration geographical locations that afford sufficient
> > numbers of men from which to sample.
> >
> > D. Program Requirements
> >
> > In conducting activities to achieve the purpose of these programs, the
> > recipient will be responsible for the activities listed under Recipient
> > Activities, and CDC will be responsible for conducting activities listed
> > under CDC Activities:
> >
> > 1. Recipient Activities
> >
> > The program will support four sites to work collaboratively with each
> > other and with Federal investigators in conducting an intervention study
> > to reduce sexual risk-taking among substance abusing MSM. At each site, 
>it
> > is expected that grantees will newly enroll a minimum of 375 men,
> > including non-injection drug and other substance-using (including 
>alcohol)
> > gay identified and non-gay identified MSM.
> >
> > The interventions to be tested should be theory-based, group-level
> > interventions appropriate for use among a culturally-diverse population 
>of
> > MSM who reside within a challenging socio-cultural context. Intervention
> > strategies should be sufficiently brief and of a technical level that
> > would facilitate rapid dissemination among community-based 
>organizations.
> > Approximately one-third of the men should identify as African American,
> > one-third as Hispanic/Latino and one-third as Caucasian at each study
> > site. Men who are recruited into the study must currently use drugs 
>and/or
> > alcohol at a heavy level and have been sexually active within the past
> > three months. Men recruited into the study can be poly-drug users
> > (including alcohol), but without current intravenous drug use. Men can 
>be
> > recruited from a variety of venues, including drug using venues, bars,
> > public sex environments known also to be sites for drug/alcohol use as
> > well as substance abuse treatment organizations. The design of the study
> > should include an attention control strategy, so that men randomized to
> > the control condition are invited to equivalent time spent in groups 
>that
> > focus on an issue of interest to this population.
> >
> > Applicants should develop (1) sampling and recruitment strategies that
> > ensure that the study includes a demographically diverse group of MSM, 
>(2)
> > culturally-sensitive measures of antecedent and outcome variables,
> > including both quantitative and qualitative assessments, (3) an
> > intervention plan that relates directly to an identified theoretical 
>model
> > of sexual risk reduction, (4) a core set of measures that will 
>facilitate
> > assessment of substance use and sexual risk behavior, (5) a sampling 
>plan
> > that will successfully recruit and retain a large number of research
> > participants whose substance use is associated with high risk sexual
> > behavior at some level, and (6) stringent safeguards for protecting
> > confidentiality of participants.
> >
> > Applicants must develop protocols and assessment instruments that will
> > increase understanding of a broad array of sociocultural, structural,
> > psychological, and behavioral factors as they relate to HIV infection 
>risk
> > in substance-using MSM. These factors must be addressed in the design of
> > intervention activities, so that the forces that are promoting high risk
> > sexual activity within these populations are addressed in the
> > intervention. Clear hypotheses should be developed to test how these
> > variables--and drug and alcohol use themselves--mediate or moderate 
>target
> > risk behaviors. After sites are funded, but before research activities
> > begin, grantees and Federal investigators will work collaboratively to
> > refine the protocols so that they fit together across sites and address
> > behavioral intervention research issues in a scientifically rigorous
> > manner.
> >
> > Collaborate with other Federally sponsored researchers, including
> > developing and using common data collection instruments and data
> > management procedures, as determined in post-award grantee planning
> > conferences.
> >
> > Recipients will be required to pool data for analysis and publication, 
>but
> > can also conduct independent site-specific analyses, as agreed to by the
> > multi-site study group. Recipients are also required to work
> > collaboratively as a study group to:
> >
> > a. Attend meeting(s) at CDC to develop collaborative research protocol.
> >
> > b. Develop the research study protocols and standardized data collection
> > forms across sites, including standardized measures of drug and alcohol
> > use and high risk sexual behaviors.
> >
> > c. Prepare an IRB protocol for approval at the local and CDC levels.
> >
> > d. Identify, recruit, obtain informed consent from, and newly enroll an
> > adequate number of study participants as determined by the study 
>protocols
> > and the program requirements.
> >
> > e. Follow study participants as determined by the study protocols.
> >
> > f. Develop the intervention and intervention procedures in collaboration
> > with the other funded investigators and implement the intervention as
> > defined in study protocols.
> >
> > g. Establish procedures to maintain the rights and confidentiality of 
>all
> > study participants.
> >
> > h. Perform laboratory tests (when appropriate) and data analysis as
> > determined in the study protocols.
> >
> > i. Collaborate and share data (when appropriate) with other 
>collaborators
> > to answer specific research questions.
> >
> > j. Conduct data analysis with all collaborators.
> >
> > k. Present and publish research findings.
> >
> > l. Participate in conference calls with all collaborators.
> >
> > m. Attend scheduled meetings with other funded grantees.
> >
> > 2. CDC Activities
> >
> > a. Provide technical assistance as needed in intervention development 
>and
> > in the design and conduct of research.
> >
> > b. Assist in the development of a research protocol for Institutional
> > Review Board (IRB) review by all cooperating institutions participating 
>in
> > the research project. The CDC IRB will review and approve the protocol
> > initially and on at least an annual basis until the research project is
> > completed.
> >
> > c. Assist as needed in designing a data management system.
> >
> > d. Assist as needed in performance of selected laboratory tests.
> >
> > e. Work collaboratively with investigators to help facilitate research
> > activities across sites involved in the same research project.
> >
> > f. Analyze data and present findings at meetings and in publications.
> >
> > E. Application Content
> >
> > Use the information in the Program Requirements, Other Requirements, and
> > Evaluation Criteria sections to develop your application. Your 
>application
> > will be scored based on the criteria listed in the Evaluation Criteria, 
>so
> > it is important to follow them in laying out your program plan. The
> > narrative should be no more than 20 double-spaced pages, printed on one
> > side with one inch margins in a 12- point font or greater. Follow the
> > directions for completing the application that are found in the Public
> > Health Service (PHS) 398 kit.
> >
> > F. Submission and Deadline
> >
> > Submit the original and two copies of PHS-398 (OMB Number 0925- 0001)
> > (adhere to the instructions on the Errata Instruction Sheet for PHS 
>398).
> > Forms are in the application kit and at the following Internet address:
> > http://www.cdc.gov/od/pgo/forminfo.htm.
> >
> > On or before July 31, 2002 submit the application to:
> >
> > Technical Information Management Section, PA <#>02136, Procurement and
> > Grants Office, Centers for Disease Control and Prevention (CDC), 2920
> > Brandywine Road, Room 3000, Atlanta, GA 30341- 4146.
> >
> > Deadline: Applications shall be considered as meeting the deadline if 
>they
> > are:
> >
> > Received on or before the deadline date.
> >
> > Late Applications: Applications which do not meet the criteria above 
>will
> > be returned to the applicant.
> >
> > G. Evaluation Criteria
> >
> > Application
> >
> > Applicants are required to provide Measures of Effectiveness that will
> > demonstrate the accomplishment of the various identified objectives of 
>the
> > grant or cooperative agreement. Measures of Effectiveness must relate to
> > the performance goal (or goals) as stated in section ``A. Purpose'' of
> > this announcement. Measures must be objective and quantitative and must
> > measure the intended outcome. These Measures of Effectiveness shall be
> > submitted with the application and shall be an element of evaluation.
> >
> > Each application will be evaluated individually against the following
> > criteria by an independent review group appointed by CDC. Applications
> > will be ranked on a scale of 100 maximum points. Applications will be
> > reviewed and evaluated based on the evidence submitted and the 
>applicant's
> > abilities to meet the following criteria:
> >
> > 1. Familiarity With and Access to the Study Population (25 points)
> >
> > a. Extent of the applicant's knowledge of issues faced by study
> > population, including substance use and sexual risk behaviors, access to
> > the study population and experience in working with the population.
> >
> > b. Existence of linkages to facilitate recruitment from and referral to
> > community-based programs providing services for the study population,
> > including letters of support given in an appendix.
> >
> > c. Feasibility of plans to involve the study population, their 
>advocates,
> > or service providers in the development of research activities and to
> > inform them of research results.
> >
> > d. Feasibility of plans for recruitment and outreach to new study
> > participants (e.g. not men currently enrolled in an ongoing study). 2.
> > Description and Justification of an Intervention and Research Plan (40
> > points)
> >
> > a. Quality of the review of the scientific literature pertinent to the
> > proposed study, including the theoretical basis for the investigation 
>and
> > relevance of research questions.
> >
> > b. The originality of the research, including the extent to which it
> > addresses important gaps in knowledge and has strong relevance for 
>guiding
> > behavioral interventions.
> >
> > c. Applicant's understanding of the research objectives as evidenced by
> > the quality of the proposed research plan, specific study design and the
> > choice of the theory to guide the intervention activities as well as the
> > quality of the plan to operationalize intervention activities.
> >
> > d. Feasibility of plan to sample, recruit, obtain informed consent and
> > newly enroll 375 study participants in a culturally and linguistically
> > appropriate manner. This includes plans for achieving a demographically
> > diverse sample within the African-American and Hispanic populations,
> > conducting multi-venue sampling.
> >
> > e. Feasibility of plan for collecting both quantitative and qualitative
> > formative research data and to follow research participants over time.
> >
> > f. Comprehensiveness of the plan to protect the rights and 
>confidentiality
> > of all participants.
> >
> > g. Thoroughness of statistical analysis plans, including data cleaning,
> > management, and substantive analyses, and plans for timely provision of
> > data for pooled analyses.
> >
> > h. Extent to which study proposal demonstrates agreement to comply with
> > multi-site research requirements (e.g., common protocol, data 
>collection,
> > and computer and data management systems).
> >
> > i. The degree to which the applicant has met the HHS Policy requirements
> > regarding the inclusion of ethnic and racial groups in the proposed
> > research. This includes: (1) the proposed plan for the inclusion of 
>racial
> > and ethnic minority populations for appropriate representation; (2) the
> > proposed justification when representation is limited or absent; (3) a
> > statement as to whether the design of the study is adequate to measure
> > differences when warranted;
> >
> > j. Provide a statement as to whether the plans for recruitment and
> > outreach for study participants include the process of establishing
> > partnerships with communities and recognition of mutual benefits.
> >
> > k. Provide general time line for conducting the research and a detailed
> > time line for the first year of the study, including measurable process
> > objectives for the first year of the study.
> >
> > 3. Demonstration of Staff's Capability to Conduct Research (20 points)
> >
> > a. Applicant's ability to carry out the proposed research as 
>demonstrated
> > by the training, experience, and expertise of the principal investigator
> > and the proposed research team and organizational setting, including
> > demonstration of ability to collect, manage, and analyze accurate data 
>in
> > a timely manner.
> >
> > b. Evidence of plan for establishing a partnership with at least one
> > community based organization to link participants with prevention and
> > medical services as needed, and to consult on study procedures as 
>needed.
> >
> > c. Demonstration of epidemiologic, behavioral intervention, clinical,
> > administrative, and management expertise needed to conduct the proposed
> > research.
> >
> > d. Demonstration that principal investigator and staff have experience
> > working with the targeted population of study participants.
> >
> > e. Demonstration that investigative team includes a staff member with
> > expertise in qualitative formative data analysis.
> >
> > 4. Staffing, Facilities, and Time-Line (15 points)
> >
> > a. Availability of qualified personnel with realistic and sufficient
> > percentage-time commitments (including an estimated staffing plan for
> > years in which intervention activities will occur); clarity of the
> > described duties and responsibilities of project personnel including 
>clear
> > lines of authority and supervisory capacity over the behavioral,
> > epidemiologic, clinical, administrative, data management, and 
>statistical
> > aspects of the research.
> >
> > b. Adequacy of the facilities, equipment, data processing and analysis
> > capacity, and systems for management of data security and participant
> > confidentiality.
> >
> > c. Adequacy of base staff to keep pace with anticipated workload.
> >
> > d. Adequacy of time-line for conducting the research.
> >
> > 5. Other (not scored)
> >
> > a. Budget: The extent to which it is reasonable, clearly justified,
> > consistent with the intended use of funds, and allowable. All budget
> > categories should be itemized.
> >
> > b. Human Subjects: The application adequately address the requirements 
>of
> > Title 45 CFR Part 46 for the protection of human subjects.
> >
> > H. Other Requirements
> >
> > Technical Reporting Requirements
> >
> > Provide CDC with original plus two copies of
> >
> > 1. annual progress reports;
> >
> > 2. financial status report, no more than 90 days after the end of the
> > budget period; and
> >
> > 3. final financial status and performance reports, no more than 90 days
> > after the end of the project period.
> >
> > Send all reports to the Grants Management Specialist identified in 
>section
> > J (``Where to Obtain Additional Information'') of this document.
> >
> > The following additional requirements are applicable to this program. 
>For
> > a complete description of each, see Attachment 1 in the application kit.
> >
> > AR-1 Human Subjects Requirements
> > AR-2 Requirements for Inclusion of Women and Racial and Ethnic
> > Minorities in Research
> > AR-4 HIV/AIDS Confidentiality Provisions
> > AR-5 HIV Program Review Panel Requirements
> > AR-6 Patient Care
> > AR-7 Executive Order 12372 Review
> > AR-9 Paperwork Reduction Act Requirements
> > AR-10 Smoke-Free Workplace Requirements
> > AR-11 Healthy People 2010
> > AR-12 Lobbying Restrictions
> > AR-22 Research Integrity
> >
> > J. Where to Obtain Additional Information
> >
> > This and other CDC announcements can be found on the CDC home page
> > Internet address-- http://www.cdc.gov Click ``Funding'' then ``Grants 
>and
> > Cooperative Agreements.''
> >
> > If you have questions after reviewing the contents of all the documents,
> > business management technical assistance may be obtained from:
> >
> >
> > Lynn Mercer, Grants Management Officer, Grants Management Branch,
> > Procurement and Grants Office, Announcement <#>02136, Centers for 
>Disease
> > Control and Prevention (CDC), 2920 Brandywine Rd. Room 3000, Mailstop
> > E-15, Atlanta, GA 30341, Telephone: (770) 488-2810, E-mail address:
> > lzm2 at cdc.gov.
> >
> > For program technical assistance, contact: Craig Studer, Deputy Chief,
> > Behavioral Intervention Research Branch, Division of HIV/AIDS
> > Prevention--IRS, National Center for HIV, STD, TB Prevention ,Centers 
>for
> > Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Mailstop
> > E-37, Atlanta, Georgia 30333, Telephone: (404) 639-1900, E- mail 
>address:
> > CStuder at cdc.gov.
> >
> >
> >
> >
>
>_________________________________
>Elaine Auld, MPH, CHES
>Executive Director
>Society for Public Health Education
>750 First St, NE, #910
>Washington, DC 20002
>phone: (202) 408-9804
>fax: (202) 408-9815
>
>SOPHE 53rd Annual Meeting
>November 8-9, 2002
>Holiday Inn Crowne Plaza
>Philadelphia, PA
>email: eauld at sophe.org
>web: www.sophe.org


_________________________________________________________________
Get your FREE download of MSN Explorer at http://explorer.msn.com/intl.asp.
-------------- next part --------------
A non-text attachment was scrubbed...
Name: SAVE THE DATE.doc
Type: application/msword
Size: 11264 bytes
Desc: not available
Url : http://mailman1.u.washington.edu/pipermail/pnwhealth/attachments/20020608/62b50e11/SAVETHEDATE.doc